This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Cardinal Health Banks on Buyouts Amid Intense Competition
by Zacks Equity Research
Cardinal Health (CAH) consistently works on launching products and carrying out acquisitions to boost revenues.
Express Scripts (ESRX) Looks Good: Stock Adds 5.8% in Session
by Zacks Equity Research
Express Scripts (ESRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Express Scripts (ESRX) in Focus: Stock Moves 5.5% Higher
by Zacks Equity Research
Express Scripts (ESRX) saw its shares rise over 5% on the day.
Express Scripts (ESRX) Q3 Earnings In Line, FY17 View Up
by Zacks Equity Research
Express Scripts Holding Company (ESRX) posted robust first-quarter numbers driven by operational cost improvement backed by focus on technology, digital tools, home delivery and specialty services.
Will CNC Q3 Earnings Come in Better Than ESRX on Oct 24?
by Zacks Equity Research
Centene (CNC) is expected to post better results in Q3 compared to Express Scripts (ESRX) on the back of solid revenue growth driven by rising membership.
Will PBM Slowdown Hamper Express Scripts (ESRX) Q3 Earnings?
by Zacks Equity Research
Lackluster performance in PBM product network and services segment is likely to mar Express Scripts' (ESRX) revenues in the third quarter.
Express Scripts (ESRX) to Buy eviCore, Fortify PBM Business
by Zacks Equity Research
Express Scripts (ESRX) is consistently trying to expand its core PBM business.
Express Scripts (ESRX) Dips on $3.6 Billion Deal to Buy EviCore Healthcare
by Madeleine Johnson
On Tuesday, shares of Express Scripts Holding Co. (ESRX) are falling, down about 1.7% in late-morning trading after the company announced plans to purchase privately-held medical benefit management company eviCore Healthcare for $3.6 billion.
Is Express Scripts Holding (ESRX) a Great Stock for Value Investors?
by Zacks Equity Research
Express Scripts Holding is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.
Express Scripts to Boost Oral Medication With Diabetes Study
by Zacks Equity Research
Express Scripts' (ESRX) new study will support oral diabetes medication and reduce related costs.
Express Scripts (ESRX) Down 2.6% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Express Scripts (ESRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Express Scripts (ESRX) Earnings Top in Q2, FY17 View Up
by Zacks Equity Research
Express Scripts (ESRX) perform well in the second quarter on the back of operational cost improvement backed by focus on home delivery and specialty services.
Healthcare Q2 Earnings Slated on Jul 25: HCA, UHS & More
by Zacks Equity Research
The healthcare sector continues to benefit from higher enrollments, mergers and acquisitions, partly offset by high expense on account of acquisition integration and investments in technology.
What's in Store for Express Scripts (ESRX) in Q2 Earnings?
by Zacks Equity Research
Despite an upbeat guidance, cutthroat competition in the niche space is likely to mar Express Scripts' (ESRX) growth in the second quarter.
Express Scripts Rides High on Increased Generic Utilization
by Zacks Equity Research
On Jul 10, we issued an updated research report on St. Louis, MO-based pharmacy benefit manager Express Scripts Holding Company (ESRX).
Express Scripts Gains from Increased Generic Utilization
by Zacks Equity Research
On Jun 27, we issued an updated research report on St. Louis, MO-based pharmacy benefit manager Express Scripts Holding Company (ESRX).
Should Value Investors Pick Express Scripts (ESRX) Stock?
by Zacks Equity Research
Let's see if Express Scripts Holding Company (ESRX) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Here's Why Mallinckrodt (MNK) Shares are Lower Today
by Madeleine Johnson
On Monday, shares of pharmaceutical company Mallinckrodt Plc. (MNK) are slipping, down about 5% to $40.50 per share in afternoon trading--MNK dropped about 8% in heavy morning trading--after a new report from short-seller Citron Research targeted the company.
New Research Reports for Oracle, Chubb, AstraZeneca & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), Chubb (CB) and AstraZeneca (AZN).
Could Amazon Be the Next Big Pharmacy Giant?
by Madeleine Johnson
Amazon is reportedly looking to expand into new territory. According to CNBC, the e-commerce giant is trying to figure out how it can break into the multi-billion-dollar pharmacy industry.
Express Scripts (ESRX) Earnings Top in Q1, FY17 View Up
by Zacks Equity Research
Express Scripts Holding Company (ESRX) posted first-quarter 2017 adjusted earnings per share of $1.33, beating the Zacks Consensus Estimate by a penny.
Top Research Reports for Today: VZ, KO, SBUX
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Verizon (VZ), Coca Cola (KO) and Starbucks (SBUX).
Will Express Scripts (ESRX) Q1 Earnings Hold a Surprise?
by Zacks Equity Research
Express Scripts Holding Company (ESRX), is scheduled to report first-quarter 2016 results on Apr 24, after market close.
Express Scripts (ESRX) Down 4.9% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Express Scripts (ESRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Express Scripts (ESRX) a Great Stock for Value Investors?
by Zacks Equity Research
Express Scripts (ESRX) seems to be agreat stock for the value investors on the back of its highly impressive value statistics.